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Abstract
Background Despite several muscle mass measures being used in the current deﬁnitions of sarcopenia, their usefulness is
uncertain because of limited data on their association with health outcomes. The aim of the study was to compare the
performance of different muscle mass measures for predicting incident osteoporosis in postmenopausal women.
Methods This study included data from 149 166 participants (aged 60.3 ± 5.5 years) as part of the UK Biobank cohort. Body
composition was assessed using bioelectrical impedance. The muscle mass measures included were total body skeletal muscle
mass (SMM) and appendicular SMM (aSMM) divided by height squared (ht2), derived residuals, SMM, SMM adjusted for body
mass (SMM/bm × 100), and aSMM normalized for body mass index (aSMM/BMI). Diagnoses of the events were conﬁrmed by
primary care physicians and coded according to the World Health Organization’s International Classiﬁcation of Diseases 10th
Revision (ICD-10: M80-M82).
Results Over a median follow-up of 6.75 (5th to 95th percentile interval, 1.53 to 8.37) years, 394 newly diagnosed cases of
osteoporosis occurred, with 40 (10.2%) cases being associated with a pathological fracture. SMM/ht2, aSMM/ht2 residual, and
SMM were lower in postmenopausal women with osteoporosis compared with women without (all P < 0.0001), while
SMM/bm × 100 (P = 0.003), but not aSMM/BMI (P = 0.59), was higher in the osteoporosis group. The unadjusted rates of
osteoporosis increased with decreasing quintiles for SMM/ht2, aSMM/ht2, residuals, and SMM (all P trend <0.0001), while
the incidence of osteoporosis increased with increasing SMM/bm × 100 (P trend =0.001), but not for aSMM/BMI
(P = 0.45). After minimally adjusting for age and after full adjustment, SMM/ht2, aSMM/ht2, and SMM were the only measure
that consistently predicted osteoporosis in the total group of postmenopausal women [hazard ratio (HR) 0.65–0.67, all
P ≤ 0.0001], in lean women (HR 0.62–0.68; all P ≤ 0.001), and women with increased adiposity (HR 0.64–0.68; all P ≤ 0.01).
In fully adjusted models, the changes in the R2 statistic were 13.4%, 11.6%, and 15.3% for the SMM/ht2 (aSMM/ht2), residual,
and SMM, but only 4.9% and 1.3% for SMM/bm × 100 and aSMM/BMI.
Conclusions Muscle mass measures adjusted for height only (SMM/ht2, aSMM/ht2) appear to be better muscle-relevant risk
factors for incident osteoporosis in postmenopausal women, including when stratiﬁed into lean participants and participants
with increased adiposity.
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Introduction
Menopause is accompanied by pronounced changes in
body composition including loss of bone (osteoporosis)
and muscle (sarcopenia), often in the presence of
increased adiposity and fat redistribution towards
central-type obesity.1–3 Osteoporosis, a skeletal disease
characterized by low bone mass and microarchitectural de-
terioration of bone tissue, predisposes to skeletal fragility
and increases fracture risk.2 It is typically diagnosed on
the basis of a bone mineral density (BMD) T-score ≤ 2.5,
as assessed by dual-energy X-ray absorptiometry (DXA).2
Because of its association with fractures, osteoporosis
is a signiﬁcant cause of morbidity and mortality and
results in substantial burden for both individuals and
healthcare systems.4 Current estimates suggest that
approximately 50% of women over 50 years old are at
risk of osteoporotic fractures.5
In contrast to osteoporosis, sarcopenia remains
poorly deﬁned, with lack of consensus about its opera-
tional deﬁnition.6 Nevertheless, it is especially common
in postmenopausal women, with prevalence reaching up
to 30% depending on the deﬁnition and population used.3
Thus far, proposed deﬁnitions are based on muscle
mass alone7–9 or combined with muscle function (e.g.
grip strength) and/or physical performance (e.g. gait
speed).10–13 Further perplexing the current debate, a
number of muscle mass measures and different threshold
for these measures have been suggested. These include
total body or appendicular muscle mass adjusted
for height only,7,8,11 height and fat mass,9 or body size
[i.e. body mass index (BMI)13 or body mass12].
Despite the plethora of muscle mass measures, there
is scarcity of data on their association with health
outcomes.
Some previous studies that explored the relationship
between osteoporosis and sarcopenia have yielded mixed
results.14–18 Studies are limited by small sample
size,14,15,17,18 or cross-sectional design,14–18 making extrap-
olation to the general population challenging. Appendicular
muscle mass adjusted for height is the most widely used
measure of sarcopenia14–18; however, there is a lack of
comparative data using other available measures of
muscle mass in relation to bone health outcomes. This is
particularly important for population groups susceptible
to poor musculoskeletal health such as postmenopausal
women.
We, therefore, compared muscle mass measures as
predictors of osteoporosis with or without pathological
fracture in a large cohort of postmenopausal women. A
secondary goal was to explore the performance of the
muscle mass measures in predicting incident osteoporosis
in postmenopausal women, when stratiﬁed into lean and
with increased adiposity.
Methods
Study population
UK Biobank is an ongoing, prospective cohort of 502 635 par-
ticipants (5.5% response rate) aged 40–69 years. All partici-
pants were recruited between 2006 and 2010 and attended
one of the 22 assessment centres across UK, where they pro-
vided sociodemographic, lifestyle, and health information
and underwent physical and medical assessments.19 The UK
Biobank protocol complied with the Declaration of Helsinki
and was approved by the North West Multi-Centre Research
Ethics Committee. Participants provided their informed con-
sent on the touchscreen before taking part. The UK Biobank
protocol is available online (http://www.ukbiobank.ac.uk/
wp-content/uploads/2011/11/UK-Biobank-Protocol.pdf). Ad-
ditional details of the UK Biobank have been published
elsewhere.19 For the present analysis, we excluded all men
(n = 229 172), premenopausal women (n = 64 091), postmen-
opausal women with a prior diagnosis of osteoporosis at
baseline, or missing information (n = 60 206). Thus, the num-
ber of participants statistically analysed totalled 149 166.
Measurements at baseline
Sociodemographic and lifestyle characteristics
Postmenopausal women completed a touchscreen question-
naire (available online: http://www.ukbiobank.ac.uk/re-
sources/) including questions on sociodemographic
characteristics, health status, and lifestyle habits. Participants
self-reported their age, sex, and ethnicity. Ethnicity was cate-
gorized as White or other (mixed, Asian, Black, Chinese, and
other). A Townsend deprivation score was computed for all
participants using information about employment, car and
home ownership, and household overcrowding.20 A higher
Townsend deprivation score is indicative of greater levels of
an area’s socio-economic deprivation.20 Participants reported
their smoking status (never, previous, or current) and their al-
cohol intake (never, previous, or current). Data on physical
activity including frequency (number of days in a typical week
that participants performed 10 min or more of walking, mod-
erate, and vigorous physical activity) and duration (minutes
spent on each activity category on a typical day) were col-
lected by asking questions similar to those included in the
International Physical Activity Questionnaire.21 For each ac-
tivity category, the frequency was multiplied by the duration
and the metabolic equivalent value (3.3 for walking, 4.0 for
moderate physical activity, and 8.0 for vigorous physical
activity), which were then summed to generate a score of
metabolic equivalent minutes of physical activity per week
for each participant.
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Medical history and current medications
Self-reported data on medical conditions were collected at
baseline by asking participants whether a doctor has diag-
nosed any cancer or diabetes. Participants reported if they
had undergone bilateral oophorectomy or hysterectomy or
were on hormone replacement therapy (HRT). Self-reported
data on fracture occurrence (yes or no) over the past 5 years
were also collected. Information on X-ray veriﬁcation was
unavailable.
Quantitative heel ultrasound
Quantitative ultrasound of the heel was performed using the
Sahara Clinical Sonometer (Hologic, Bedford, Massachusetts)
according to a standardized protocol. Trained staff checked
if participants were able to undertake both left and right heel
ultrasound measurement. Those with open wounds, breaks
or sores around the heel, or metal parts (such as pins) in
the heel did not undertake measurement of that heel. Each
centre used the same machine model, and quality control
was performed with a phantom on a daily basis as per man-
ufacturer’s instructions. The mean values for BMDs (g/cm2)
and BMD T-scores for the left and right heel were computed.
Anthropometric and bioelectrical impedance
measurements
Height was measured using the SECA 240 height measure
(SECA, Hamburg, Germany). Participants removed their socks
and footwear and stood ﬂat footed with their heels against a
back plate. Body mass was measured to the nearest 0.1 kg
using a segmental body composition analyser (Tanita
BC-418MA, Tokyo, Japan). Height and weight were used to
calculate BMI as weight (kg) divided by height squared (m2).
Waist circumference was measured at the level of the umbi-
licus using a tape measure. All these measurements were
performed by trained staff.
Skeletal muscle mass (SMM) was calculated using the
bioelectrical impedance analysis (BIA) equation published
previously by Janssen and colleagues22:
SMM kgð Þ ¼ ht2=R0:401 þ gender3:825ð Þ
þ age 0:071ð Þ þ 5:102;
where ht2 = height in centimetres squared; R = resistance
in ohms; for gender, men = 1 and women = 0; and age is
in years.
Appendicular SMM (aSMM), representing the sum of SMM
in arms and legs, was calculated using the equation provided
by Wang et al.23: aSMM = SMM/1.33.
Muscle mass measures
For the purpose of the present analysis, we included ﬁve
muscle mass measures previously used in sarcopenia deﬁni-
tions.7–13 Unadjusted SMM was also considered for compari-
sons. Speciﬁcally, SMM and aSMM were divided by height
squared (SMM/ht2 and aSMM/ht2).7,8,10,11 Based on the
deﬁnition proposed by Delmonico et al.9 and previously pub-
lished methods,24 the relationship between appendicular
fat-free mass on height (m) and fat mass (kg) was modelled
using linear regression analysis and the standardized resid-
uals of the regression were computed. Muscle mass was also
adjusted for body size; aSMM was divided by BMI (aSMM/
BMI),13 and SMM was divided by body mass and multiplied
by 100 (SMM/bm × 100).12,25
Assessment of outcome
Via the Health and Social Care Information Centre for English
and Welsh participants and the Information Services Depart-
ment for Scottish participants, we ascertained the diagnosis
of osteoporosis with or without a pathological fracture until
31 January 2016 for England and Wales and 30 November
2015 for Scotland. Diagnoses of the events were conﬁrmed
by primary care physicians and coded according to the World
Health Organization’s International Classiﬁcation of Diseases
10th Revision (ICD-10: M80-M82).
Statistical analysis
For database management and statistical analysis, we used
SAS software, version 9.4 (SAS Institute Inc., Cary, NC, USA).
We compared means and proportions by the standard
normal z-test and the χ2 statistic. Statistical signiﬁcance was
set at a level of 0.05 on two-sided tests.
We analysed the prognostic signiﬁcance of the muscle
mass measures by means of both categorical and continuous
analysis. In categorical analysis, we plotted unadjusted
incidence rates by quintiles of the muscle mass measures’
distribution. For the continuous analysis, we used Cox pro-
portional hazard regression to calculate standardized relative
hazard ratios while initially adjusting for age and then
allowing for additional covariables and potential confounders
in the total group and in groups stratiﬁed by BMI (<25 and
≥25 kg·m2), waist circumference (<88 and ≥88 cm), and
whole body fat percentage (<35 and ≥35%).26,27
Using the forward stepwise procedure, we included base-
line age, ethnicity, physical activity, use of HRT, self-reported
smoking and alcohol use, and self-reported diagnosed cancer
and diabetes as covariables. We checked the proportional
hazards assumption by the Kolmogorov-type supremum test,
as implemented in the PROC PHREG procedure of the SAS
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package. Finally, we applied the generalised R2 statistic to
assess the risks explained in Cox regression28 by adding the
different muscle mass measures separately to models already
including the previously mentioned covariables.
Results
Baseline characteristics
The baseline characteristics of the postmenopausal women
with and without osteoporosis are presented in Table 1.
The women with diagnosed osteoporosis were older
(P < 0.0001) and had lower fat mass (P < 0.0001), SMM
(P < 0.0001), and aSMM (P < 0.0001) compared with those
without osteoporosis. There were no difference in physical
activity between the groups (P = 0.80). Mean heel BMD at
baseline was lower in the osteoporosis group (P < 0.0001)
and had experienced more fractures in the previous 5 years
(P < 0.0001). SMM/ht2, aSMM/ht2, residuals, and SMM were
lower in the osteoporosis group (all P < 0.0001), while
SMM/bm × 100 (P = 0.003), but not aSMM/BMI (P = 0.59),
was higher in the osteoporosis group (Table 2).
Risk prediction by muscle mass measures
Median follow-up was 6.75 (5th to 95th percentile interval,
1.53 to 8.37) years. There were 394 newly diagnosed cases
of diagnosed osteoporosis that included 40 (10.2%) cases as-
sociated with a pathological fracture.
As aSMM was calculated from SMM, only SMM/ht2 is
reported in the subsequent results. The unadjusted rates
for osteoporosis (Figure 1; Table S1) increased with decreas-
ing quintiles of SMM/ht2 and SMM (both P < 0.0001), while
SMM/bm × 100 increased with increasing quintiles
(P = 0.001). No relationship existed for SSM/BMI (P = 0.45).
The rate of osteoporosis for the residual measure of
sarcopenia also increased with decreasing quintiles
(P < 0.0001). After minimally adjusting for age, the predictive
value of the muscle mass measures in the total group, and
separately in lean participants and those with increased adi-
posity (Figure 2, Table S2), the sarcopenia measure including
Table 1 Baseline characteristics of postmenopausal women with and without osteoporosis
Without osteoporosis (n = 148772) Osteoporosis (n = 394) P
Demographics
Age (years) 60.3 ± 5.5 62.6 ± 4.9 <0.0001
Age at menopause (years) 49.7 ± 5.1 48.1 ± 6.2 <0.0001
Relative deprivation 1.46 ± 2.98 1.45 ± 2.89 0.97
Ethnicity 0.57
European, n (%) 133098 (89.5) 356 (90.4)
Other, n (%) 15674 (10.5) 38 (9.6)
Anthropometry
Body weight (kg) 70.9 ± 13.3 64.9 ± 11.2 <0.0001
Body height (cm) 161.9 ± 6.2 160.6 ± 6.2 <0.0001
BMI (kg/m2) 27.1 ± 5.0 25.2 ± 4.3 <0.0001
Waist circumference (cm) 85.0 ± 12.2 81.8 ± 11.3 <0.0001
Fat mass (kg) 27.1 ± 9.7 23.4 ± 7.8 <0.0001
SMM (kg) 17.1 ± 2.64 16.0 ± 2.20 <0.0001
aSMM (kg) 12.8 ± 1.6 12.0 ± 1.7 <0.0001
Lifestyle, bone, and health
Physical activity (MET-min/week) 1534 (212–8849) 1511 (200–8241) 0.80
Alcohol use 0.028
Never, n (%) 8952 (6.0) 32 (8.1)
Previous, n (%) 5551 (3.7) 22 (5.6)
Current, n (%) 134157 (90.2) 340 (86.3)
Smoking 0.50
Never, n (%) 85494 (57.5) 234 (59.4)
Previous, n (%) 50498 (33.9) 124 (31.5)
Current, n (%) 12187 (8.2) 36 (9.1)
Bone and health
Heel BMD (g/cm2) 0.50 ± 0.12 0.41 ± 0.10 <0.0001
Heel BMD T-score (SD) 0.72 ± 1.06 1.50 ± 0.93 <0.0001
Fractures in last 5 years, n (%) 16834 (11.3) 121 (30.7) <0.0001
HRT, n (%) 70015 (47.1) 220 (55.8) 0.0006
Bilateral oophorectomy, n (%) 8161 (5.5) 34 (8.6) 0.006
Hysterectomy, n (%) 17312 (11.6) 64 (16.2) 0.005
Self-reported cancer, n (%) 15636 (10.5) 81 (20.6) <0.0001
Self-reported diabetes, n (%) 6017 (4.0) 15 (3.8) 0.81
Values are arithmetic mean ± SD, geometric mean (5th to 95th percentile interval), or number of subjects (%). aSMM: appendicular skel-
etal muscle mass; BMD, bone mineral density; BMI: body mass index; HRT, hormone-replacement therapy; MET, metabolic equivalent of
task; SD, standard deviation; SMM: skeletal muscle mass.
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SMM and height (SMM/ht2) or SMM alone, was consistently
predictive of osteoporosis (P ≤ 0.01) in the total group and in
participants with a BMI above and below 25 kg/m2, waist cir-
cumference above and below 88 cm, and body fat percentage
above and below 35%. The residuals were not predictive in
participants with increased adiposity as presented by BMI
(P ≤ 0.11) and waist circumference (P = 0.076), while
SMM/bm × 100 and aSMM/BMI showed mixed results. In
fully adjusted models (Table 3), these results remained un-
changed after accounting for age, ethnicity, self-reported
smoking and alcohol use, physical activity, use of HRT, and
self-reported diagnosed cancer and diabetes as covariates.
In addition, these results remained unchanged even after
excluding 40 participants diagnosed with osteoporosis associ-
ated with a pathological fracture (Table 3).
Lastly, by adding each measure of muscle mass to the re-
spective models already containing the previously mentioned
covariates, the changes in the R2 statistic were 13.4%, 11.6%,
and 15.3% for SMM/ht2, residual, and SMM, but only 4.9%
and 1.3% for SMM/bm × 100 and aSMM/BMI.
Discussion
Our prospective study in postmenopausal women showed
that SMM and aSMM adjusted for height squared and
Table 2 Comparison of muscle mass measures based on muscle mass at baseline in postmenopausal women with and without osteoporosis
Without osteoporosis (n = 148772) Osteoporosis (n = 394) P
Muscle mass measures
SMM/ht2 (kg/m2) 6.51 ± 0.71 6.19 ± 0.71 <0.0001
aSMM/ht2 (kg/m2) 4.89 ± 0.53 4.66 ± 0.53 <0.0001
Residual 0.018 ± 0.76 0.254 ± 0.75 <0.0001
SMM (kg) 17.1 ± 2.64 16.0 ± 2.20 <0.0001
aSMM/bm × 100 (%) 24.5 ± 3.35 25.0 ± 3.14 0.003
aSMM/BMI (m2) 0.48 ± 0.08 0.49 ± 0.08 0.59
aSMM/ht2, appendicular skeletal muscle mass divided by height squared; bm, body mass; BMI, body mass index; SMM/ht2, skeletal muscle
mass divided by height squared. Residual is the appendicular skeletal muscle mass adjusted for height and fat mass using multiple regres-
sion analysis.
Figure 1 Rates of newly diagnosed osteoporosis by quintiles of muscle mass measures in 149 116 postmenopausal women. aSMM/ht2, appendicular
skeletal muscle mass divided by height squared; bm, body mass; BMI, body mass index; SMM/ht2, skeletal muscle mass divided by height squared.
Residual is the appendicular skeletal muscle mass adjusted for height and fat mass using multiple regression analysis. ^, similar to aSMM/ht2.
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SMM alone were better and more consistent muscle-
relevant risk factors for osteoporosis compared with mea-
sures adjusted for fat mass, body mass, or BMI. This was
evident in both lean women and women with increased
adiposity. These results remained signiﬁcant following
adjustments for covariables and potential confounders.
Taken together, our ﬁndings suggest that SMM/ht2 and/or
aSMM/ht2 can be universally used as measures of muscle
mass when identifying postmenopausal women with in-
creased osteoporotic risk, while measures including body
mass or fat appear to be less consistent.
In our analysis in the total group, although all muscle mass
measures were predictive of incident osteoporosis, SMM/ht2
and SMM explained 13.4% and 15.3% of the variability in the
incident osteoporosis, whereas the SMM/bm × 100 and
aSMM/BMI explained only 4.9% and 1.3%, respectively.
Several, although not all,14,18 studies have demonstrated a
positive association between height-adjusted appendicular
lean body mass (assessed by DXA) and BMD or osteoporosis
in postmenopausal women or in a mixed population of men
and women.15–17 Other muscle mass measures utilized in cur-
rent sarcopenia deﬁnitions are poorly characterized in rela-
tion to incident osteoporosis thus far, with our present
longitudinal data extending the literature in this area and
suggesting that SMM adjusted for fat mass, body mass, or
BMI are less closely associated with this bone health-related
outcome.
These results were conﬁrmed in subgroup analyses, in
which the postmenopausal women were stratiﬁed into lean
and those with increased adiposity. SMM/ht2, aSMM/ht2,
and SMM alone were consistently predictive of incident oste-
oporosis, while the prognostic signiﬁcance of the residuals
were less consistent across subgroups and mostly absent
for SMM/bm × 100 and aSMM/BMI. Previous studies have
explored the combined effects of increased adiposity and
muscle mass or strength on osteoporosis.29–32 By identifying
sarcopenic individuals as those fulﬁlling at least two of the
following three criteria with speciﬁc cut-offs, that is, low
Figure 2 Standardised hazard ratios for osteoporosis adjusted for age in relation to the different muscle mass measures in the total group, in those
with a body mass index (BMI) above and below 25 kg/m2, above and below a waist circumference (WC) of 88 cm, and a body fat percentage (%) above
and below 35%. Hazard ratios given with 95% conﬁdence intervals express the risk associated with a 1-SD increase in the explanatory variables. aSMM/
ht
2
, appendicular skeletal muscle mass divided by height squared; bm, body mass; SMM/ht
2
, skeletal muscle mass divided by height squared. Residual
is the appendicular skeletal muscle mass adjusted for height and fat mass using multiple regression analysis. Open and ﬁlled circles represent the total
and lean groups, respectively, while the larger ﬁlled circles represent those with increased adiposity. ^, similar to aSMM/ht
2
.
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aLM/ht2, gait velocity, and grip strength, Huo et al.29 demon-
strated in 680 elderlymen andwomen (mean age: 79 ± 9 years,
65% female) that sarcopenic obesity was signiﬁcantly associ-
ated with a lower hip BMD compared with non-sarcopenic
obesity (T-score 1.39 ± 1.24 vs. 0.79 ± 1.33; P < 0.01).
Similarly, osteoporosis has been reported to be more preva-
lent in sarcopenic and sarcopenic obese women compared
with non-sarcopenic, non-obese women.31,32 Conversely, af-
ter 5 years of follow-up, Scott et al. reported no difference
in total hip BMD when they compared sarcopenic obese with
non-sarcopenic, non-obese men.30 These results were indif-
ferent when two sarcopenia deﬁnitions were tested based
on aLM/BMI and grip strength or aLM/ht2 and grip strength
and/or gait speed.
The limited performance of the SMMmeasures adjusted for
fat mass, body mass, or BMI on incident osteoporosis in the
sub-analyses of the current studymay reﬂect an equally impor-
tant role of leanmass and fatmass on bone health of postmen-
opausal women, which may have synergistic or opposing
effects on BMD.15,16,18,33,34 Indeed, both muscle mass and fat
mass imposemechanical loading in theweight-bearing skeletal
sites.35 Additional non-mechanical beneﬁts of muscle mass on
bone may be because muscle and bone share genetic, endo-
crine, and lifestyle determinants.36 The effects of fat mass on
bone formation and resorption are mechanistically mediated
by bone active hormones, which originate from pancreatic β
cell (i.e. insulin, amylin) or adipocytes (i.e. oestrogens, leptin,
and adiponectin), with these effects reported to be positive
or negative.37 Furthermore, increased fat mass commonly
results in increased levels of pro-inﬂammatory cytokines
(interleukin-6, tumour necrosis factor-alpha), which promote
bone resorption and subsequent bone loss.37
We showed between 22% and 29% lower risk for incident
osteoporosis for each SD increase in SSM/ht2 (and
aSMM/ht2) among postmenopausal women with increased
adiposity when classiﬁcation into subgroups was based on
BMI, and WC or total body fat percentage. These associations
appeared to be less prominent when BMI was utilized to strat-
ify the women into lean and those with increased adiposity,
compared with waist circumference and body fat percentage.
These ﬁndings support previous suggestions that body fat per-
centage and waist circumference may be more appropriate
than BMI, when assessing sarcopenic obesity in relation to
health outcomes,38,39 given that the latter fails to unravel the
amount and distribution of fat and muscle mass.40 This is crit-
ical for ageing individuals who may experience an increase in
fat mass and ectopic fat deposition in muscle and bone,38
therefore making it difﬁcult to accurately determine the status
of the SMM of a person. Indeed, in the present study, muscle
mass measures that involved fat resulted in mixed results as
both parts of the measure can vary as a ratio (e.g. aSMM and
BMI). Conversely, when utilizing SMM/ht2 or aSMM/ht2, the
Table 3 Adjusted standardized hazard ratios for osteoporosis in relation to measures for sarcopenia in lean and in participants with increased
adiposity
Anthropometric
measures
Muscle mass measures
SMM/ht2 (kg/m2)a Residual SMM (kg) SMM/bm × 100 (%) aSMM/BMI (m2)
Hazard ratios (95% CI)
Total group 0.67 (0.59–0.75)**** 0.81 (0.72–0.90)*** 0.65 (0.58–0.73)**** 1.25 (1.12–1.39)**** 1.13 (1.01–1.25)*
BMI <25 kg/m2 0.68 (0.56–0.83)*** 0.79 (0.67–0.92)** 0.64 (0.54–0.77)**** 0.91 (0.76–1.10) 0.79 (0.67–0.94)**
BMI ≥25 kg/m2 0.78 (0.66–0.93)** 0.89 (0.76–1.04) 0.77 (0.65–0.91)** 1.19 (0.96–1.48) 1.07 (0.87–1.31)
WC <88 cm 0.66 (0.57–0.78)**** 0.81 (0.70–0.92)** 0.67 (0.58–0.78)**** 1.18 (1.02–1.36)* 1.05 (0.92–1.20)
WC ≥88 cm 0.71 (0.57–0.87)*** 0.83 (0.68–0.99)* 0.64 (0.52–0.80)**** 1.25 (0.94–1.65) 1.02 (0.79–1.31)
Body fat <35% 0.62 (0.52–0.76)**** 0.68 (0.57–0.81)**** 0.63 (0.53–0.76)**** 0.92 (0.72–1.17) 0.84 (0.69–1.02)
Body fat ≥35% 0.71 (0.61–0.83)**** 0.78 (0.67–0.92)** 0.69 (0.59–0.80)**** 1.25 (0.97–1.61) 1.02 (0.83–1.25)
After excluding 44 participants diagnosed with osteoporosis associated with a pathological fracture
Total group 0.54 (0.45–0.65)**** 0.74 (0.64–0.87)*** 0.82 (0.77–0.87)**** 1.08 (1.04–1.12)**** 1.17 (1.04–1.30)**
BMI <25 kg/m2 0.57 (0.43–0.77)*** 0.72 (0.58–0.90)** 0.81 (0.75–0.89)**** 0.97 (0.92–1.03) 0.79 (0.66–0.95)*
BMI ≥25 kg/m2 0.70 (0.54–0.92)** 0.86 (0.69–1.08) 0.89 (0.82–0.97)** 1.07 (0.99–1.15) 1.13 (0.91–1.42)
WC <88 cm 0.54 (0.43–0.69)**** 0.74 (0.61–0.90)** 0.84 (0.78–0.90)**** 1.06 (1.01–1.10)* 1.08 (0.94–1.25)
WC ≥88 cm 0.61 (0.45–0.84)** 0.78 (0.59–1.03) 0.82 (0.74–0.91)*** 1.08 (0.99–1.18) 1.04 (0.79–1.37)
Body fat <35% 0.51 (0.39–0.68)**** 0.59 (0.46–0.76)**** 0.82 (0.75–0.89)**** 0.97 (0.90–1.05) 0.85 (0.69–1.03)
Body fat ≥35% 0.59 (0.46–0.75)**** 0.69 (0.56–0.87)** 0.83 (0.77–0.90)**** 1.08 (0.99–1.17) 1.04 (0.83–1.30)
The Cox models accounted for baseline age, ethnicity, self-reported smoking and alcohol use, physical activity, use of hormone replace-
ment therapy, and self-reported diagnosed cancer and diabetes as covariates. Hazard ratios given with 95% conﬁdence intervals (CI) ex-
press the risk associated with a 1-SD increase in the muscle mass measures. Residual is the appendicular skeletal muscle mass adjusted for
height and fat mass using multiple regression analysis. aSMM/ht2, appendicular skeletal muscle mass divided by height squared; bm, body
mass; BMI, body mass index; SMM/ht2, skeletal muscle mass divided by height squared; WC, waist circumference. Signiﬁcance of the haz-
ard ratios:
aSimilar to aSMM/ht2.
*P ≤ 0.05;
**P ≤ 0.01;
***P ≤ 0.001; and
****P ≤ 0.0001.
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focus is placed upon muscle mass as height is constant. Similar
associations were observed for SMM alone.
Strengths of our study include the prospective design, the
large sample size, and the wide age range of postmenopausal
women (40–70 years) from the general population. We chose
not to utilize available cut-offs, but to test these muscle mass
measures as continuous variables, overcoming the inherent
limitation of the cut-off approach, which is generally not rec-
ommended for continuously distributed variables.41 Further-
more, available cut-offs for muscle mass measures have
been established in reference populations with different
baseline characteristics (i.e. age, ethnicity, and disease status)
from those characteristics of our cohort or by using DXA to
determine body composition. The limitations of the study
should also be acknowledged. We used BIA to assess body
composition, which may be less accurate than imaging tech-
niques such as DXA, magnetic resonance imaging, and com-
puted tomography.42 BIA is, however, an established option
for detecting sarcopenia by the European Working Group
on Sarcopenia in Older People3 and the Asian Working Group
on Sarcopenia43; it is inexpensive and it can be easily included
in geriatric assessments. Estimations of SMM and aSMM
were based on equations; therefore, some degree of over
or underestimation is possible, albeit constant. Importantly,
SMM and aSMM represent SMM only, whereas BIA output
variables of fat-free mass additionally include masses of the
liver, kidneys, heart, bone, and connective tissue44 and,
therefore, have been suggested to the relationship between
muscle mass and BMD.45 In this study, the focus was placed
upon muscle mass measures, rather than measures of muscle
strength or performance, which require exploration in follow-
up studies. Lastly, our ﬁndings were in community-based
postmenopausal women only and cannot necessarily apply
to postmenopausal women in nursing homes, those with
advanced illness or men.
Conclusions
In summary, our comparative approach of published muscle
mass measures used in available sarcopenia deﬁnitions
suggest that more ‘pure’ measures of skeletal muscle
(SMM/ht2, aSMM/ht2, and SMM alone) may be better
muscle-relevant risk factors for osteoporosis as opposed to
measures including fat mass, body mass, and BMI, irrespec-
tive of the level of adiposity, at least in postmenopausal
women. These ﬁndings have implications for the detection
of sarcopenia and sarcopenic obesity in this clinically relevant
population at high risk of musculoskeletal diseases. Future
studies are required to investigate the association between
muscle mass measures and bone health in elderly men with
varying degrees of adiposity.
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